Cara Therapeutics, Inc.

NasdaqCM:CARA Rapport sur les actions

Capitalisation boursière : US$19.1m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Cara Therapeutics Bilan de santé

Santé financière contrôle des critères 4/6

Cara Therapeutics possède un total de capitaux propres de $11.6M et une dette totale de $39.7M, ce qui porte son ratio d'endettement à 342.1%. Son actif total et son passif total sont $72.5M et de $60.9M.

Informations clés

342.1%

Ratio d'endettement

US$39.68m

Dette

Ratio de couverture des intérêtsn/a
Argent liquideUS$56.62m
Fonds propresUS$11.60m
Total du passifUS$60.90m
Total des actifsUS$72.50m

Mises à jour récentes de la santé financière

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Feb 16
We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Oct 25
Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Jul 20
Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Recent updates

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Jul 18
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%

We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

May 29
We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S

May 25
Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Feb 16
We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

Dec 19
The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

Nov 04
News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Oct 25
Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Jul 20
Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

Jun 04
Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

Mar 11
News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

Feb 15
Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

Feb 06
We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

Oct 18
We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients

Sep 28

Cara Therapeutics hires new finance chief

Sep 12

Cara Therapeutics: All Eyes On Korsuva Launch Metrics

Sep 01

Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients

Aug 19

Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M

Aug 08

Calls A Much Safer Way To Buy Cara Therapeutics

Jun 24

We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Jun 15
We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts

May 12
Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts

Taking A (Speculative) Position In Cara Therapeutics

Mar 21

Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth

Mar 09
Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth

Cara Therapeutics: De-Risked And Extremely Attractive

Dec 25

Checking Back In On Cara Therapeutics

Nov 01

Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA

Aug 21

The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically

Aug 15
The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically

Cara Therapeutics: 200% Upside Possible With FDA Approval

Aug 11

Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive

Jul 19

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de CARA ( $63.9M ) dépassent ses passifs à court terme ( $13.9M ).

Passif à long terme: Les actifs à court terme de CARA ( $63.9M ) dépassent ses passifs à long terme ( $47.0M ).


Historique et analyse du ratio d'endettement

Niveau d'endettement: CARA dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de CARA est passé de 0% à 342.1% au cours des 5 dernières années.


Bilan


Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: CARA dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: CARA dispose d'une marge de trésorerie suffisante pour 1.8 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 10.7 % chaque année.


Découvrir des entreprises saines